1. Home
  2. OCG vs SILO Comparison

OCG vs SILO Comparison

Compare OCG & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oriental Culture Holding LTD

OCG

Oriental Culture Holding LTD

SELL

Current Price

$1.67

Market Cap

3.3M

ML Signal

SELL

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$1.43

Market Cap

3.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCG
SILO
Founded
2018
2010
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Apparel
Sector
Consumer Discretionary
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.1M
IPO Year
2019
2011

Fundamental Metrics

Financial Performance
Metric
OCG
SILO
Price
$1.67
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
38.0K
★ 46.1K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
★ 9.09%
N/A
EPS Growth
N/A
★ 57.98
EPS
★ N/A
N/A
Revenue
N/A
★ $72,102.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$0.22
52 Week High
$19.29
$7.95

Technical Indicators

Market Signals
Indicator
OCG
SILO
Relative Strength Index (RSI) 56.72 18.64
Support Level $1.65 $0.30
Resistance Level $1.76 $4.80
Average True Range (ATR) 0.11 0.15
MACD 0.02 0.03
Stochastic Oscillator 62.16 20.11

Price Performance

Historical Comparison
OCG
SILO

About OCG Oriental Culture Holding LTD

Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. The company generates revenue through listing service fees, transaction fees, and other revenues collected from traders.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: